Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aclaris Therapeutics (ACRS) EPS (Weighted Average and Diluted) (2019 - 2025)

Aclaris Therapeutics has reported EPS (Weighted Average and Diluted) over the past 7 years, most recently at -$0.16 for Q4 2025.

  • Quarterly results put EPS (Weighted Average and Diluted) at -$0.16 for Q4 2025, up 86.78% from a year ago — trailing twelve months through Dec 2025 was -$0.53 (up 69.01% YoY), and the annual figure for FY2025 was -$0.53, up 69.01%.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$0.16 at Aclaris Therapeutics, down from -$0.12 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for ACRS hit a ceiling of -$0.02 in Q4 2023 and a floor of -$1.21 in Q4 2024.
  • Median EPS (Weighted Average and Diluted) over the past 5 years was -$0.31 (2022), compared with a mean of -$0.32.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): skyrocketed 95.12% in 2023 and later plummeted 5950.0% in 2024.
  • Aclaris Therapeutics' EPS (Weighted Average and Diluted) stood at -$0.37 in 2021, then dropped by 10.81% to -$0.41 in 2022, then skyrocketed by 95.12% to -$0.02 in 2023, then plummeted by 5950.0% to -$1.21 in 2024, then surged by 86.78% to -$0.16 in 2025.
  • The last three reported values for EPS (Weighted Average and Diluted) were -$0.16 (Q4 2025), -$0.12 (Q3 2025), and -$0.13 (Q2 2025) per Business Quant data.